Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer

ABSTRACT: In the study, we analyzed six pairs of differentially expressed genes between breast cancer tissues and their corresponding adjacent normal tissues, identifying KIF20A as significantly upregulated in breast cancer. Further functional analyses confirmed that KIF20A is a central regulator within the breast cancer regulatory network. It is involved not only in cell proliferation and migration but may also play a role in the invasion and metastasis of breast cancer. The aberrant expression of KIF20A suggests that it could be a potential target for the diagnosis and treatment of breast cancer, providing a critical direction for further research.

ORGANISM(S): Homo sapiens

PROVIDER: GSE280284 | GEO | 2025/10/24

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer

Project description:Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer

| PRJNA1177580 | ENA

Identification of KIF20A binding partners using IP-mass spectrometry analysis

Project description:Breast cancer stem cells (BCSCs), known to fuel TNBC malignancy, are now being exploited as the vulnerability for TNBC treatment. In this study, we dissected the transcriptome of BCSCs and identified Kinesin Family Member 20A (KIF20A) as an essential gene for BCSC survival and TNBC tumorigenesis. To understand the potential mechanism, we infected MDA-MB-231 cells with either control or V5-tagged KIF20A followed by V5 antibody pull down and mass spectrometry to identify KIF20A interaction proteins that may mediate its effect on gene regulation and TNBC cancer stem cell phenotype.

2025-09-30 | PXD060031 | Pride

Identification of KIF20A as a vulnerability for breast cancer stem-like cells in triple negative breast cancer

Project description:Triple-negative breast cancer (TNBC), being both aggressive and highly lethal, poses a significant challenge in terms of treatment. Its heterogeneity and lack of hormone receptors or HER2 expression further restrict the availability of targeted therapy. Breast cancer stem cells (BCSCs), known to fuel TNBC malignancy, are now being exploited as the vulnerability for TNBC treatment. Here, we dissected the transcriptome of BCSCs and identified Kinesin Family Member 20A (KIF20A) as an essential gene for BCSC survival and TNBC tumorigenesis. Depletion or pharmacologic inhibition of KIF20A impairs BCSC viability, tumor initiation and development in vitro and in vivo. Mechanistically, KIF20A regulates BCSC stemness through modulating the oxidative phosphorylation (OXPHOS) pathway in mitochondria, which is repressed by a member of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex, SMARCA4. Therapeutically, treatment with a KIF20A inhibitor sensitizes TNBC xenograft tumors to standard-of-care chemotherapy. Our study highlights the significance of targeting KIF20A to exploit BCSC vulnerabilities in TNBC.

2025-10-09 | GSE298177 | GEO

Identification and validation of KIF20A for predicting prognosis and treatment outcomes in patients with breast cancer.

Project description:Breast cancer is a leading cause of cancer-related deaths among women globally. It is imperative to explore novel biomarkers to predict breast cancer treatment response as well as progression. Here, we collected six breast cancer samples and paired normal tissues for high-throughput sequencing. By differential expression analysis, we found 1687 DEGs and identified the top 10 hub genes, including TOP2A, CDK1, BUB1B, KIF11, CCNA2, BUB1, CCNB1, KIF20A, DLGAP5 and CDC20. Univariate and multivariate Cox analyses on the METABRIC database and GSE96058 dataset demonstrated that KIF20A was an independent prognostic predictor for overall survival. KIF20A was positively correlated with cell cycle phases, including the cell cycle process, cycle G2 M phase transition and cell cycle DNA replication initiation. Single-cell analyses revealed that KIF20A was enriched in fibroblasts and endothelial within breast cancer stroma. Meanwhile, multidrug resistance (MDR) genes ABCB1, ABCC1 and ABCG2 were co-expressed with KIF20A in fibroblasts and endothelial cells within the stroma. MTABRIC database confirmed that high expression of KIF20A was positively correlated with treatment efficacy in patients with breast cancer. In conclusion, KIF20A could be served as a predictive biomarker for breast cancer prognosis and treatment outcomes. KIF20A may play a significant role by regulating cell cycle progression and modulating stromal progression in breast cancer. Our findings provided novel molecular insights that can guide personalized treatment strategies in breast cancer.

| S-EPMC11682246 | biostudies-literature

KIF20A/MKLP2 regulates the division modes of neural progenitor cells during cortical development

Project description:Balanced symmetric and asymmetric divisions of neural progenitor cells (NPCs) are crucial for orderly progression of brain development, but the underlying mechanisms are not fully understood. Here, we report that mitotic kinesin KIF20A/MKLP2 interacts with RGS3 and plays a crucial role in controlling the division modes of NPCs during the mouse cortical neurogenesis. KIF20A is selectively expressed by daughter progenitors in NPC divisions. Knockdown of KIF20A causes dislocation of RGS3 from the intercellular bridge (ICB) of dividing NPCs, impairs the function of EphrinB-RGS cell fate signaling complex, and leads to a transition in NPCs from proliferative to differentiative divisions. Germ-line and inducible knockout of KIF20A causes a loss of progenitor cells and neurons and results in thinner cortex and ventriculomegaly. Interestingly, loss-of-function of KIF20A induces early cell cycle exit and precocious neuronal differentiation without causing substantial multinucleation or apoptosis in mutant NPCs. Our results thus uncover a novel RGS-KIF20A axis in regulation of cell division mode and suggest a potential link of cytokinesis control within the ICB to regulation of cell fate determination.

2018-05-14 | GSE108624 | GEO

KIF20A promotes the development of soft tissue sarcoma by activating the PI3K-AKT signaling pathway

Project description:Soft tissue sarcoma (STS) is a group of malignancies that can appear in any part of the body. The prognosis of STS patients remains unsatisfactory, mainly due to metastasis and recurrence. Upregulation of KIF20A is associated with poor prognosis of STS patients, but its downstream mechanism is unknown. In the present study, we found that downregulation of KIF20A in the STS cell line HT-1080 inhibits cell proliferation, migration, and invasion and induced cell apoptosis and G2/M arrest in vitro. In addition, downregulation of KIF20A in HT-1080 repressed tumorigenesis of STS in a xenograft mouse model. Pathway analysis showed, that downregulation of KIF20A led to suppression of downstream PI3K-AKT and NF-κB pathways. Specifically, the phosphorylation of AKT at Ser473 was inhibited. Taken together, our results indicate that KIF20A plays an important role in the development of STS by inhibiting cell proliferation, migration, invasion via the PI3K-AKT signaling pathway. Therefore, KIF20A is a potential therapeutic target in STS.

2020-11-23 | GSE140074 | GEO

Identification of KIF20A as a vulnerability for breast cancer stem-like cells in triple negative breast cancer

Project description:Identification of KIF20A as a vulnerability for breast cancer stem-like cells in triple negative breast cancer

| PRJNA1268475 | ENA

Cucurbitacin B-induced G2/M cell cycle arrest of conjunctival melanoma cells mediated by GRP78-FOXM1-KIF20A pathway

Project description:Conjunctival melanoma (CM) is a rare and fatal malignant eye tumor, it is life-threatening, mainly because of the lack of diagnostic biomarkers or drug access. In this study, we deciphered a novel anti-CM mechanism of a natural tetracyclic compound isolated from a Cucurbitaceae family plant and named as Cucurbitacin B (CuB). We found that CuB remarkably inhibited the proliferation of CRMM2 cells at a submicromolar level (IC50=0.15 μM) without toxicity to normal cells via G2/M cell cycle arrest and subsequent cell apoptosis. RNA-seq screening identified the Kinesin family member 20A (KIF20A) as a key gene which was abolished by the CuB treatment and proved to be a downstream effector of FOXM1 pathway. Further target identification by the activity-based protein profiling (ABPP) chemoproteomic approach revealed that 78 KDa Glucose-Regulated Protein (GRP78) is a potential target of CuB. Several lines of evidence demonstrated that CuB interacted with GRP78 and bound with a Kd value of 0.11 μM. Furthermore, functional experiments showed that CuB suppressed the ATPase activity of GRP78 both in human recombinant GRP78 and cellular lysates. Knockdown of the GRP78 gene significantly induced the downregulation of FOXM1 and related pathway genes including KIF20A, underlying an interesting therapeutic perspective. Taken together, our current work proved a substantial therapeutic potential of the traditional medicine CuB, and it needs to be explored further for future CM therapies.

2022-05-31 | GSE192359 | GEO

Homo sapiens

Project description:DNA hypermethylation in breast cancer: breast cancer tissues vs. normal breast tissues

| PRJNA154299 | ENA

Tumor circadian clock strength influences metastatic potential and predicts patient prognosis in Luminal A breast cancer

Project description:To investigate circadian clocks in human breast tumors, 43 pairs of human samples (tumor and matched normal breast tissues from the same patient) were collected to run bulk-RNAseq, including 29 pairs of Luminal A, 3 pairs of Luminal B, 2 pairs of HER2 and 9 pairs of Triple-negative breast cancer

2024-01-26 | GSE233242 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data